Some experts, however, insisted that the phase-3 trials are necessary and should be prioritised, over offering unlicensed vaccines to any section of the population.
The volunteers will be administered the vaccine five times over a period of six months and their blood samples will be tested during the period.
Unlike other COVID-19 vaccines in development, this one is delivered via the nose, often the initial site of infection.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting Phase I and II randomized, double-blind and placebo-controlled clinical trials of Covaxin.
The Indian regulatory authorities are working with the company to ensure smooth procedural functioning.